Among the 20 somatic-BRCA1/2-mutated tumor samples, there was one heterozygous BRCA2 mutation that lacked clear biallelic inactivation at the time of archival tumor collection prior to the Study 19 trial and two BRCA2 mutations predicted as subclonal somatic by the SGZ algorithm. Here, BRCA2 is linked to neoplasm.